Does Sotolaxib (AMG510) have a big impact on vision?

Sotorasib (AMG510, Sotorasib) is a cancer drug used to treat adults with advanced non-small cell cancer (NSCLC) whose cells have special genetic changes. This change occurs in the KRAS gene and is called "KRAS G12C." Sotorasib contains the active substance sotorasib and is given when the disease has progressed after systemic therapy (treatment that affects the entire body).

Judging from the currently known clinical trial data and research results, the main side effects of sotorasiib are mainly concentrated in the digestive system, lungs and skin, including nausea, vomiting, diarrhea, fatigue, rash and other common adverse reactions. Effects on vision are not listed as one of the common side effects of sotoraxib.

However, any drug may cause uncommon or specific adverse reactions, which may vary among individuals. Although the main mechanism of action of sotoraxib is to target the KRAS protein carrying the G12C mutation, its impact on various systems throughout the body still needs to be comprehensively evaluated. In rare cases, patients may experience specific vision-related adverse reactions, such as visual impairment. However, these conditions are rare, and the specific mechanisms are not fully understood.

As a new type of anti-cancer drug, its potential adverse reactions and effects still need to be confirmed through more long-term observations and studies. In order to accurately assess the impact of sotoracib on vision, patients should pay close attention to changes in their physical condition while using the drug. If the patient develops any vision-related discomfort symptoms such as blurred vision, double vision, visual field loss, etc. during medication, he should report it to the doctor immediately so that the treatment plan can be adjusted in a timely manner.